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                              INTRODUCTION
History 
The development of protienuria in patients with diabetes mellitus has been described in the eighteenth century by 
Cotugno and it was Richard Bright who postulated in 1836 that albuminuria reflects renal disease. Although renal lesions in 
diabetic patients have been well known in the nineteenth century, they were usually regarded as non-specific consequences 
of hypertension. It  was only in 1936 that  Kimmelstiel and Wilson recognized nodular homogenous glomerular lesions 
(nodular diabetic glomerulosclerosis) as a diabetes specific complication 1, 2. Later documented that the renal lesion was part 
of the more general clinical syndrome of microangiopathy. 
Keen et al (1969) in the United Kingdom and Parving et al (1976) in Denmark were the first to note that urinary 
albumin excretion rates are elevated in some patients with types1 and 2 diabetes3,4. There is now consensus that a lowish but 
supranormal albumin excretion rate in the urine ('microalbuminuria') is a powerful predictor of renal (and cardiovascular) 
events 5. 
Persistent  albuminuria,  that  is,  greater  than  300  mg/24  h  or  200  μg/min,  is  the  clinical  hallmark  of  the 
manifestation of diabetic nephropathy (DN). This clinical definition is valid in both types 1 and 2 diabetes. 
Dimension of the Problem 
               In most countries, DN has become the leading cause of ESRD6. According to the United States Renal Data 
System7 in 1999 DN was the primary diagnosis in 42.8 per cent (38,160 of 89,252) of incident patients7 an increase by 238 
per cent  compared to 1990. In  2000, the proportion of  diabetics amongst  patients reaching ESRD varied considerably 
between different countries, for example, 14.6 per cent in the Netherlands, 22 per cent in Australia, 25 per cent in Sweden, 
and 36.1 per cent in Germany, but it was consistently on the increase in all countries.
              The prevention and management of diabetes and its renal complications is thus an immense global challenge. 
Registry figures tend to underestimate the renal burden posed by diabetes because it is under represented as illustrated by 
our own observations8. In 1998–2000, diabetes mellitus was found as a comorbid condition in no less than 48.9 percent of 
patients admitted for renal replacement therapy in Heidelberg8. 
        
              Classical features of Kimmelstiel Wilson's disease were observed in only in 60 per cent, that is, large kidneys, 
massive proteinuria (>1 g/24 h) with or without retinopathy. Atypical presentation consistent with ischaemic nephropathy 
was  seen  in  13  per  cent  and  known  primary  renal  disease  (e.g.  polycystic  kidney  disease,  analgesic  nephropathy, 
glomerulonephritis) with superimposed diabetes in 27 per cent of cases. For the diabetic patient with ESRD, survival is 
similar irrespective of whether he or she suffers from DN or primary non-diabetic renal disease9. 
              Inadequate medical care for the diabetic with renal complications is illustrated by the finding that in 11 per cent of  
the patients the diagnosis of diabetes had not even been made at the time of admission to the renal unit. This may result 
from the fact that hyperglycaemia is often self-corrected when patients lose weight as a result of anorexia.
Fig. 1 Cumulative risks (a) to develop proteinuria and (b) to progress to renal failure in patients with types 1 and 2 
diabetes10. 
PATHOMECHANISMS: 
Pathology 
Macroscopic Changes 
               Enlargement of the kidney is found in newly diagnosed patients with type 1 diabetes. Similarly, in experimental  
animals it is seen within 4 days of the onset of diabetes. It results from tubular hypertrophy and interstitial expansion11. It is 
thought to be related to hyperfiltration and stimulated active reabsorption 12. 
Light Microscopic Changes 
The Glomerulus 
  Glomerular enlargement is an early feature of both human and experimental diabetes and is the result of increases 
in capillary length and diameter.  Glomerular  enlargement is  also present  in established nephropathy,  mean glomerular 
volumes are 4–6 × 10 6 μm 3 in patients with types 1 and 2 diabetes compared to normal values of 1–2.3 × 10 6 μm3 13. The 
reasons for enlargement are unclear—initially it may be because of altered glomerular haemodynamics and hyperfiltration, 
and later because of a compensatory response to capillary closure and global glomerulosclerosis. 
      
           The hallmark of diabetic glomerulopathy is diffuse mesangial expansion, associated with nodule formation in a 
minority of patients (Fig. 2). Most patients with long-standing diabetes show an increase in periodic acid–schiff (PAS)-
positive matrix material, although these changes are much more prominent in those with clinical nephropathy. Initially, this 
material is central to the tuft but later it  expands and effectively obliterates the capillaries eventually leading to global 
glomerulosclerosis11. 
Fig. 2 Nodular diabetic glomerulosclerosis. PAS reaction. Magnification 100×. Courtesy of Prof R. 
Waldherr, Heidelberg, Germany. 
            Nodules are more or less pathognomonic for diabetes and were the first glomerular pathological abnormality 
described by Kimmelstiel and Wilson. They comprise acellular, eosinophilic, and lamellated structures, usually located at 
the periphery of the tuft. Their pathogenesis is unclear, but they may represent obliterated capillary microaneurysms, or 
result from focal mesangiolysis at the junction of the glomerular basement membrane (GBM) with the mesangium. This 
would  lead  to  endothelial  cell  detachment  and  subsequent  ballooning  into  the  capillary,  quickly  followed  by  matrix 
deposition11.  These features  are not  universally found in patients with microalbuminuric  type  2 diabetes  patients  14.  A 
proportion of these patients have an appearance which is more suggestive of glomerular ischaemia or tubulointerstitial 
disease. Patients with type 2 diabetes with clinical nephropathy or retinopathy have glomerular changes similar to type 1 
diabetes 15.  Capsular drops of PAS-positive matrix material lying between the matrix membrane and parietal epithelium of 
Bowman's capsule are commonly seen, but their significance is unclear. 
          In ESRD, glomeruli appear as sclerosed hyalinized structures and a percentage is actually resorbed. This global  
sclerosis is due to a combination of mesangial expansion and ischaemia secondary to afferent arteriolar hyalinosis 16. 
Tubulointerstitium 
             Armanni–Ebstein lesions, that is, glycogen-rich granules in proximal tubular cells, result from glucose overload and 
are preventable by reversing glycosuria. Tubulointerstitial expansion contributes to whole kidney enlargement. It is also a 
feature of established nephropathy and is found even in a significant number of microalbuminuric type 2 diabetic patients. 
Its causes are almost certainly different in early diabetes and established nephropathy. Acute changes in the juxtaglomerular 
apparatus are seen within hours of development of diabetes in the rat. More subtle long-term abnormalities in this structure 
have also been described  in  patients  with microalbuminuric  type  1 diabetes  and may reflect  increased activity of  the 
tubuloglomerular feedback mechanism and possibly an upregulation of the renin–angiotensin system (RAS) 17. Afferent and 
efferent  arteriolar  hyalinosis  is  a  characteristic  feature  of  diabetic  patients  and  is  more  prominent  in  those  with 
microalbuminuria18 or more advanced renal disease. 
Immunofluorescence Microscopy 
             Non-specific linear staining for immunoglobulin (IgG) (mainly IgG4) and albumin is found in the GBM, tubular 
basement membrane (TBM), and Bowman capsule. No direct correlation is found with the severity of glomerulopathy or 
nephropathy. Its pathophysiological significance is unclear 11
Electronmicroscopy   
Glomerulus 
              Its structure is normal at the onset of type 1 diabetes, but GBM thickening up to three times the normal range of 
270–359 nm is an almost universal feature in patients with duration of diabetes greater than 10 years. This thickening is 
more marked in patients with microalbuminuria and clinical nephropathy. There is an accumulation of type IV collagen 
with a net reduction in heparin sulfate proteoglycan. This combination disrupts both GBM structure and its electrostatic 
charge properties. It is thus thought to result in abnormal permselectivity and leakage of circulating proteins11. 
          In normal man, the ratio of cellular to matrix components is about 1 : 1. The mean fractional volume of the 
mesangium is between 14– 20 per cent  of the glomerular tuft19.  In  contrast,  in patients with DN, the mesangium can 
comprise over 40 per cent of the total tuft volume. This accumulation disrupts the microfibrillar structure of the mesangium, 
altering its porosity to proteins and weakening attachments to the endothelium and GBM, thus perhaps predisposing to 
nodule formation11. 
           Nodules comprise matrix of similar composition, but with a prominent accumulation of microfibrils. In advanced 
nephropathy, thin irregular segments of GBM lined by an abnormal looking endothelium may be found, representing either 
new capillary growth or microaneurysms. This may lead to microscopic haematuria that is occasionally seen in diabetes as it 
is in thin basement membrane disease. 
Tubulointerstitium
 
              The structure of the TBM is largely similar to the GBM, but it is almost twice as wide. In diabetes, the TBM 
increases  to  about  two  to  three  times  its  normal  width  and  often  appears  split  20,  possibly permitting  penetration  of 
macromolecules into the interstitial space and thus favouring the development of fibrosis. Early tubulointerstitial expansion 
results from an increase in cellular components21 followed by collagen accumulation later. 
Pathomechanisms of Microvascular Damage: 
              The microvascular lesions of the kidney in diabetes mellitus had variably been ascribed to generation of advanced 
glycation  endproducts  (AGE),  cumulation  of  sorbitol,  activation  of  protein  kinase  C  (PKC),  and  activation  of  the 
hexosamine pathway. A unifying concept has recently been proposed by Brownlee 22. He provided evidence that in insulin-
insensitive tissues hyperglycaemia increases the delivery of glucose-derived intermediates as the metabolic substrate for 
mitochondrial oxidation. Increased mitochondrial oxidation leads to the generation of reactive oxygen species (ROS). ROS 
are responsible for the following four metabolic abnormalities: (a) accumulation of methylglyoxal and other substrates leads 
to  the  generation  of  early Amadori  products  and  late  AGE respectively,  (b)  furthermore  activation  of  PKC by ROS, 
particularly the β-isoenzyme, (c) activation of the polyol pathway causing accumulation of sorbitol, and finally (d) also 
activation of the hexosamine pathway. 
           Major attention has recently been paid to the pathogenic role of AGE. As shown in Fig. 3, glucose (but more 
importantly also other compounds such as methylglyoxal) interact with the α and γ amino groups of amino acids to form 
Schiff bases that rearrange spontaneously to yield Amadori products. These are non-enzymatically transformed into highly 
reactive early Amadori products, for example,  methylglyoxal, dideoxyglucosone, deoxyglucosone, etc. In the course of 
weeks, heterocyclic advanced fluorescent AGEs are generated, which cross-link proteins and interact with several receptors, 
the most important of which is receptor for AGE (RAGE).
 
Fig. 3 Glucose (but more importantly also other compounds such as methylglyoxal) interact with the α 
and γ  amino groups of  amino acids  to  form Schiff  bases,  which  rearrange  spontaneously to  yield 
Amadori  products.These  are  non-enzymatically  transformed  into  highly  reactive  early  Amadori 
products,  for  example,  methylglyoxal,  oxyglucosone,deoxyglucosone.  
           Activation of the RAGE triggers ROS formation and promotes translocation of the transcription factor NF-κB, a 
central switch for inflammatory processes into the nucleus. The relevance of AGE for DN is illustrated by the fact that the 
course  of  DN  is  accelerated  in  animals,  which  are  transgenic  for  RAGE  23.  Important  secondary  mediators  for  the 
development of renal damage are transforming growth factor β (TGFβ)  24, locally generated angiotensin II  12, endothelin, 
and several other cytokines. 
Renal Pathophysiology 
               It has been known since decades that the glomerular filtration rate (GFR) is elevated in diabetes mellitus 25. This 
has now been well documented in type 1 diabetes26 and, although this has remained more controversial, equally in type 2 
diabetes27. 
           The mechanisms underlying hyperfiltration have been clarified in animal experiments 28. In rats with diabetes, 
hyperfiltration as well as hyperperfusion and enhanced glomerular capillary hydraulic pressure have been well documented. 
This constellation is due to preferential afferent renal vasodilatation with the resulting impairment of renal autoregulation. 
This was also documented in patients with type 129 and type 2 diabetes30.  Dilatation of the preglomerular vessels will 
increase the vulnerability to hypertension (or conversely vulnerability to ischaemia from hypotension). A larger proportion 
of aortic blood pressure is transmitted into the glomerular capillary bed causing 'glomerular hypertension'. This fact also 
explains why even blood pressure (BP) values in the upper normal range are injurious to the vasodilated  kidney of diabetic 
patients. 
          As shown in Fig. 4, glomerular hypertension resulting from afferent vasodilatation and efferent vasoconstriction, 
in conjunction with altered glomerular permeability causes proteinuria, activation of proximal tubular epithelial cells, renal 
fibrosis and ultimately nephron loss and renal failure. ACE inhibitors interfere with these processes as described in detail 
below. 
Fig. 4 Schema of glomerular hypertension, injury from proteinuria, and the effect of ACE inhibitors. 
           Apart from elevated systemic and glomerular capillary pressure, proteinuria plays a major pathogenetic role.  
Remuzzi 31 had postulated that proteinuria is not only a marker of adverse renal prognosis, but actually a 'nephrotoxin'. This 
concept  has  been  amply confirmed by studies  showing that  proximal  tubular  epithelial  cells  acquire  an  inflammatory 
phenotype and upregulate expression of angiotensinogen12, endothelin32, and cytokines, when they have been confronted 
with a  protein  overload in  the tubular  fluid.  Albumin was shown to be less  injurious  than complement  factors,  iron-
containing proteins and oxidized lipids33.
           Angiotensin II, endothelin, and cytokines are then secreted in an abluminal direction into the interstitium where  
they activate peritubular fibroblasts and lead to interstitial fibrosis. This sequence has also been shown in vivo by studies in 
the amphibian kidney34. 
        
               In the past, it was felt to be a paradox that in diabetes the kidney responds so favourably to pharmacological 
blockade  of  the  RAS,  although  the  systemic  RAS  is  suppressed.  It  has  recently  been  documented,  however,  that 
hyperglycaemia upregulates the local synthesis of angiotensinogen35 in proximal tubular epithelial cells, which possess all 
components of the RAS and are able to generate angiotensin II. In the tubular fluid and the interstitium, the concentration of 
angiotensin II is orders of magnitude greater than in the circulation 36.
          Furthermore, the expression of the angiotensin II receptor subtype 1 is upregulated37. These facts may explain the 
finding that despite low plasma renin activity (PRA) in patients with diabetes, RAS blockade causes a pronounced increase 
in renal plasma flow38 under hyperglycaemic, but not under euglycaemic conditions 39.
       
           In diabetes, renal sodium (Na) handling is abnormal. This explains the frequent findings of Na retention and 
hypervolaemia.  Proximal  tubular  reabsorption  of  Na  is  increased  as  a  result  of  increased  activity of  the  Na,  glucose 
cotransporter  40.  As a result, distal  Na delivery is  diminished and GFR is increased via the tubuloglomerular feedback 
mechanism,  leading  to  hyperfiltration  41.  In  addition,  insulin  directly  increases  distal  tubular  Na  reabsorption  42. 
Furthermore, increased angiotensin II in tubular fluid was recently shown to also activate Na channels in the collecting duct 
36. Na retention is a prominent factor in the genesis of hypertension of the diabetic patient. 
Why Do Diabetic Patients Develop Albuminuria And Proteinuria? 
               In the past, it had been thought that negatively charged molecules of the GBM are reduced, particularly sialic acid 
and heparan sulfate, normally repel negatively charged anionic albumin. As a result glomerular permselectivity would be 
reduced so that albumin molecules can escape into the glomerular filtrate. Reduced negative charge density of the GBM has 
not been consistently confirmed 43. 
               It was also thought that in later stages of DN, disruption of the texture of the basal membrane creates gaps and 
holes (Fig. 5) and allows high molecular weight serum proteins to escape into the filtrate.
 
Fig.  5  Schema  of  the  genesis  of  selective  albuminuria  and  non-selective  proteinuria.  
   
          
          Recent insights into podocyte function and specifically identification of proteins of the slit membrane 44 have led 
to  the concept  that  the podocyte is  a  prime player  in  the genesis of  proteinuria.  Indeed,  in experimental  diabetes  the 
expression  of  one  permeability  controlling  protein,  nephrin,  is  abnormally  low  and  is  restored  by  administration  of 
angiotensin II receptor blockers 45,46. It is also of interest that in experimental diabetes, podocyte damage is the first sign of 
renal injury 47. Diminished podocyte numbers have been documented in animals and patients with diabetes48. Podocytes are 
postmitotic and can no longer proliferate. If glomeruli increase in size, each podocyte has to cover an ever larger domain, 
ultimately exceeding the capacity of the podocyte. 
           This discrepancy causes loss of podocytes by desquamation, apoptosis or necrosis, denudation of the basement 
membrane, synechia formation, and ultimately glomerulosclerosis  44. When tubular epithelial cells are exposed to higher 
protein loads, they acquire an inflammatory phenotype and amplify renal damage as outlined above. 
Stages of Diabetic Nephropathy:
               There are few renal diseases where the cause is as predictable as in DN. This has led to a 
scheme proposed by Mogense`n which is valid in type1 diabetes but less consistently so in type 2. 
Diabetic nephropathy can be divided in to five stages59, 60.
Stage-I
               Occurs at the onset of the disease. It is characterized by a 30 % to 40 % increase in GFR 
above normal has been documented primarily is patients with new onset type 1 diabetes , this returns to 
normal within several weeks to a few months after instituting insulin therapy. This hyper filtration is 
associated with enlarged kidneys and increased intraglomerular pressure, which may causes transient 
increase in albumin excretion.
Stage-II
              Characterized by normal albumin excretion < 20 mcg/ min or < 30 mcg/24 hrs regardless of 
the  duration  of  the  disease.  Some  patients  maintain  their  hyperfiltration  which  may  be  a  poor 
prognostic indicator for subsequent DN 61.
Stage-III (Incipient Nephropathy)
   Characterized by microalbuminuria at  rest  .This is defined as elevated excretion rates of 
albumin between 20 –200 mcg /min (30-300 mg/24h). In general,  patients with lowers amounts of 
microalbuminuria (20-70 mcg/min) have either elevated / normal GFR that are higher than those with 
more microalbuminuria (70-200 mg/min). GFR begins to decline during the incipient stage of diabetic 
nephropathy.
At this stage, BP, are often higher (although in normal range) than in non diabetic subjects. It 
may increases to abnormally high levels during exercise. In general BP increase 3 to 4 mmHg per year.
Stage – IV (Overt Nephropathy)
 Characterized by clinical  protienuria that  is  a level of urinary protein that  is  detectable by 
simple tests.  Thus overt  nephropathy is  clinical  as urinary protein excretion exceeding 0.5 g/24 h. 
Albumin is not the only protein excreted at  the stages, clinical  protienuria corresponds to albumin 
excretion rates exceeding 200 mcg/min or 300 mg/24 hr. Early in the clinical course of overt diabetic 
nephropathy, the GFR may be in the normal ranges, but usually declines slowly but steadily.
             Although the rate of fall in GFR may vary markedly among patients, the decrease in GFR is 
fairly constant within each patient. The average GFR decline is approximately 1 ml/min/month. During 
this stage of diabetic nephropathy, BP increases approximately 7mmHg per year; Thus hypertension 
eventually occurs in almost all patients. Aggressive treatment of elevated BP slows the rate of decline 
of the GFR. At this point, aggressive treatment of elevated glucose concentration has little effect. Once 
the process of nephron destruction is underway, it seems independent of the inciting cause, although 
lowering the BP is definitely helpful.
Stage – V –ESRD
  It is similar to kidney failure resulting from any other cause. However disproportionate shares 
have diabetic nephropathy. Although only 3 % of the population is known to have diabetes, nearly 50 
% of patients starting dialysis have RF caused by DM. Signs symptoms include progressive weakness, 
lethargy,  fluid  retention  ,  anorexia,  nausea,  vomiting,  diarrhea,  hiccups,  pruritis,  difficulty  in 
controlling hypertension, anaemia & electrolyte disturbance. 
            However the patients with ESRD resulting from diabetes are more symptomatic at higher level 
of GFR than patients with nondiabetic causes of kidney failure, that is, GFR does not have to be as low 
for diabetic patients to start experiencing difficulties.
Table 1: The Stages Of Diabetic Nephropathy 
Stage Glomerular filtration Albuminuria Blood pressure 
Time 
interval a 
Renal hyperfunction Elevated  Absent Normal At 
diagnosis 
Clinical latency High normal Absent 
Microalbuminuria 
(Incipient Nephropathy)
Within the 
normal range 
20–200 μg/min 
(30–300 mg/day) 
Rising within or 
above the 
normal range 
5–15 
Macroalbuminuria/proteinuria (overt 
nephropathy) 
Decreasing 200 μg/min (300 
mg/day) 
Increased 10–15 
End Stage Renal failure Diminished Massive Increased 15–30 
Extrarenal  Complications  Associated  With  Diabetic  Nephropathy 
Table 2: Major microvascular and macrovascular complications in patients with diabetic nephropathy 
Microvascular Complications 
Retinopathy 
Polyneuropathy Including Autonomic Neuropathy 
Gastroparesis, Diarrhoea/Obstipation, Detrusor Paresis, Painless Myocardial   Ischaemia,        Erectile 
Impotence, And Supine Hypertension/ Orthostatic Hypotension 
Macrovascular Complications 
Coronary Heart Disease, Left Ventricular Hypertrophy, And Congestive Heart Failure 
Cerebrovascular Complications (Stroke) 
Peripheral Artery Occlusive Disease 
Mixed Complications 
Diabetic Foot (Neuropathic, Vascular) 
           Diabetic retinopathy is present in virtually all type 1 diabetic patients with nephropathy 49, but only 50–60 per 
cent of proteinuric patients with type 2 diabetes suffer from retinopathy  50, so that the absence of retinopathy does not 
preclude the diagnosis of Kimmelstiel Wilson glomerulosclerosis. Nevertheless absence of retinopathy is one argument, 
amongst others, favouring the indication for a renal biopsy (see below). The risk of blindness because of severe proliferative 
retinopathy or maculopathy is substantially greater in diabetic patients with nephropathy. Retinopathy tends also to progress 
more rapidly in patients with DN, so that more frequent ophthalmological examination is clearly indicated, that is, at yearly 
or half-yearly intervals. 
          Many patients with DN have polyneuropathy. Sensory polyneuropathy is an important aspect of the diabetic foot 
problem .  Motor and sensory neuropathy may cause areflexia,  wasting, and sensory disturbances such as paraesthesia, 
anaesthesia, impaired perception of vibration, and pain, but the most vexing clinical problems are the result of autonomic 
polyneuropathy. It involves frequently the cardiocirculatory system  51 causing abnormally low pulse rate variability (RR 
interval) and unchanged heart rate in upright position, but more sophisticated techniques such as uptake of radioanalogues 
of norepinephrine by the heart show that subclinical abnormalities are practically always found. Further consequences of 
autonomic polyneuropathy are gastroparesis, that is, delayed emptying of gastric contents into the gut, and diarrhoea, or 
constipation (often alternating with each other). 
          These problems are caused by impaired intestinal innervation, often complicated by intestinal bacterial overgrowth 
because of stasis. Finally, urogenital abnormalities are frequent such as erectile impotence or detrusor paresis with delayed 
and incomplete emptying of the bladder. 
          The major macroangiopathic complications are stroke, coronary heart disease, and peripheral vascular disease. 
These complications are again up to five fold more frequent in diabetic patients with and without DN. 
          The onset of DN is a turning point in the life of a patient with diabetes. The presence of DN greatly increases the 
mortality of a patient with types 1 and 2 diabetes. This had been documented by 52, decades ago. They found that compared 
to the background population type 1 diabetic patients without proteinuria had only a slightly,  that is, two- to threefold 
elevated, mortality.  In  contrast,  mortality was increased by a factor  of 20–200 in patients with proteinuria.  The major 
increase in risk starts as soon as microalbuminuria has set in 53, but a higher risk is found even in upper quartile of normal 
range albuminuria. The mechanistic link between microalbuminuria and cardiovascular death is not well understood. It is 
widely thought that the presence of microalbuminuria reflects generalized endothelial cell dysfunction and increased risk of 
atherogenesis. It is associated with many cardiovascular risk factors, such as elevated BP, dyslipoproteinaemia, increased 
platelet aggregation, increased C-reactive protein (CRP) concentration and others.
          An added risk factor is presumably the association of microalbuminuria with autonomic polyneuropathy 51, which 
predicts deaths from myocardial infarction or arrhythmia (sudden death).  Further cardiac abnormalities associated with 
microalbuminuria are cardiac hypertrophy 54 and impaired left ventricular diastolic function. 
          The prognosis is even grimmer in diabetic patients with proteinuria, that is, with clinically manifest DN 52. In the 
past, the estimated 10-year cumulative death rate was up to 70 per cent in type 155 as well as in patients with type 2 diabetes 
56. It has substantially decreased in recent years with better control of hypertension, better care of coronary heart disease, 
and  improved  management  of  patients  by renal  replacement  therapy.  For  instance  in  the  Heidelberg  series,  mortality 
decreased substantially in the decades between 1966 and 1985 57.
         There is an ongoing discussion whether the high death rate in DN is explained by established cardiovascular risk 
factors or whether uraemia amplifies the cardiovascular risk because of the presence of additional non-classical risk factors.
        In  this  context,  it  is  of interest  that  experimentally even minor impairment  of renal  function,  for  example, 
uninephrectomy, causes drastic acceleration of atherogenesis 58.
 
Diagnostic Procedures 
             DN remains a clinical diagnosis based upon the detection of proteinuria, although many 
patients  will  also  have  hypertension  and  retinopathy.  The  diagnostic  procedures  to  establish  the 
diagnosis of DN and its complications comprise (a) determination of albuminuria or proteinuria, (b) 
blood pressure measurement, (c) estimation of GFR and in selected cases, and (d) renal biopsy.
Microalbuminuria:
Definition
            Microalbuminuria is defined as excretion of 30 – 300 mg albumin per 24 hr (20 –200 mcg/min) 
in at least 2 out of 3 nonketotic sterile urine samples over a period of 6 months.
Methods:
       Five methods are available for assessing for the presence of microalbuminuria.
1.) Measuring albumin in 24 hr urine.
2.) Measuring albumin in a specifically timed shorter urine collection period (Exampl:4 hrs).
3.) Measuring albumin in overnight urine sample (i.e. Between going to sleep and waking up in the 
morning).
4.) Measuring albumin to creatinine rate in a random urine sample.
5.) Measuring the albumin concentration.
              Because urinary volume in so critical to the concentration of albumin measured, simply 
measuring the albumin concentration is not generally recommended as a screening test if one of the 
other approaches is available62.
              Timed urine collections & 24 hr  urine collections are the least convenient for patients. An 
overnight urine collection is less inconvenient but albumin execretion rate overnight urine collection is 
less inconvenient but because of recumbency and little activity the albumin excretion rate overnight is 
approximately 25 % less than during the day ( upright posture and exercise induced albumin excretion) 
this may not be a drawback,because an abnormal value in an overnight collection is more certain to be 
a valid diagnosis.
             The albumin / creatinine ratio is the simplest of four valid tests to assess microalbuminuria.  
ACR of 30 mcg /mg ( 3.5 m/m mol) or higher have a high degrees ( 95 % to 100 %) of both sensitively 
and specificity in predicting microalbuminuria when measured by 24 hr or timed urine collection63, 64. A 
ratio  measured  in  a  sample  collected  on  rising  in  the  morning  correlate  much  more  closely with 
microalbuminuria measured by other means. 
             The Council Diabetes Mellitus National Kidney Foundation 65 has recommended the simple 
ACR over other methods.The measurement of microalbuminuria is only reliable if confounding factors 
have been excluded such as fever, physical exercises urinary tract infection, non diabetic renal disease, 
hematuria from other causes, heart failure, and uncontrolled hypertension.
Flow Chart for Diagnosis of Incipient and Advanced Nephropathy:
 Renal biopsy 
 
        Renal biopsy is certainly not indicated when a type 1 diabetic patient has retinopathy and when the time course is 
consistent with DN. Renal biopsy should be considered, however, when protienuria is present less than 10 years after the 
onset of type 1 diabetes. In type 2 diabetes, this argument is unreliable because the onset of type 2 diabetes is often not 
known. The presence of dysmorphic erythrocytes, erythrocyte casts, or cellular casts is not a feature of DN and should 
prompt investigations to exclude glomerulonephritis or vasculitis, if necessary by renal biopsy. Other indications are rapid 
deterioration of renal function or elevated serum creatinine without urine abnormalities. Needless to say that prior to renal 
biopsy renal ultrasonography is indicated which by itself may already yield a diagnosis. 
Table 3: Potential Indications for Renal Biopsy in Patients with Diabetes
Biopsy not indicated when 
Typical evolution of renal disease 
Concomitant retinopathy 
Biopsy should be considered when 
Renal manifestations are seen atypically (<10 years) early in type 1 diabetes 
Dysmorphic erythrocytes/casts are found (nephritic sediment) 
Rapid deterioration of renal function of unknown cause is noted 
Elevated serum creatinine without urine abnormalities 
Heavy proteinuria (>5–8 g/day) persists despite lowering of blood pressure 
MANAGEMENT OF MICROALBUMINURIA AND PROTEINURIA 
           Once urinary albumin excretion is raised, it  may not be possible to stop progression of 
nephropathy completely but it is certainly possible to delay the process substantially. 
Blood Glucose Control
           Studies examining the effect of tight blood glucose control on progression of nephropathy have 
been too small or too short to demonstrate convincing benefit66, 67. However, it is obviously extremely 
important to maintain good blood glucose control for other reasons.
 Reduction of Intraglomerular Pressure
            As described above, raised intra glomerular pressure is the hallmark of diabetic nephropathy 
and a major factor in its progression. It rises primarily because of angiotensin II constrictor effects on 
the  efferent  glomerular  arteriole.  Thus  first  line  therapy  in  the  secondary  prevention  of  diabetic 
nephropathy aims to reduce intraglomerular pressure using inhibitors of the renin-angiotensin system.
             In young, type 1 diabetic patients with early nephropathy but ‘‘normal’’ blood pressure,  
numerous  studies  have demonstrated that  prescription of  an  ACE inhibitor  reduced progression  to 
protienuria compared with placebo. Initial blood pressure was generally 130/80 mm Hg at entry to 
these studies and around 120/75 mm Hg on treatment. A meta-analysis has confirmed these beneficial 
effects, demonstrating an average 65% risk reduction in the development of protienuria and a threefold 
increase in the likelihood of regression to normal albumin excretion. 68 
Almost all of this effect was independent of changes in systemic blood pressure and thus has 
been  attributed  to  specific,  intraglomerular  effects  of  ACE  inhibition.  In  most  of  these  studies, 
maximum doses of drug have been used.
            
   In  type  2  diabetes,  several  studies  have  been  reported  in  microalbuminuric  but 
‘‘normotensive’’ individuals, show benefit with ACE inhibitors compared with placebo, in terms of 
reduction in the numbers progressing to protienuria and in one, stabilization of serum creatinine over 
five years69 .This benefit is also at least partly independent of blood pressure lowering. Several large 
studies have been performed in hypertensive patients. In type 1 diabetic patients with protienuria and 
rising serum creatinine, addition of ACE inhibition compared with placebo to blood pressure control 
using other classes of antihypertensive therapy, significantly reduced the numbers reaching a combined 
end point of death, need for dialysis, or doubling of the serum creatinine70.
            
  In microalbuminuric71or proteinuric72, 73 type 2 diabetic patients, prescription of an angiotensin 
II receptor antagonist (ATIIRB) significantly reduced the rate of progression of nephropathy but had no 
effect  on  cardiovascular  outcomes.  In  the  diabetes  subgroup  of  the  Heart  Outcomes  Prevention 
Evaluation study, changes in albumin excretion were difficult to interpret because of methodological 
problems.74 The  apparent  significant  reduction  in  macro  vascular  end  points  in  those  patients 
randomized to ramipril may have been due to a difference in 24 hour blood pressure not reflected in 
clinic blood pressure measurements. Thus in type 1 and type 2 diabetic patients with microalbuminuria 
or protienuria, prescription of an inhibitor of the renin-angiotensin system, titrated up to the maximum 
tolerated dose,  is  the first  line in  management,  regardless of  initial  blood pressure.  There is  often 
concern that patients,  particularly those with type 2 diabetes,  may have atheromatous renovascular 
disease and that prescription of an ACE inhibitor or ATIIRB may precipitate acute renal failure.
            
   There is no reliable screening test for Reno vascular disease and it is important not to deny 
patients the potential benefits of renin-angiotensin system inhibition. Thus renin-angiotensin system 
inhibitors  should  be  tried  in  all  patients,  unless  in  the  rare  case  where  there  is  a  definite 
contraindication. Patients should begin with the smallest dose, which should be titrated up gradually, 
with serum creatinine and potassium being checked 1–2 weeks after each change in dose. A small 
(20%) rise in serum creatinine is common, but this should plateau. If the creatinine rises steadily, the 
drug should be withdrawn.
 
Systemic Blood Pressure Control
              Numerous studies have demonstrated the importance of reducing systemic blood pressure as 
well as intraglomerular pressure in delaying the rate of fall of glomerular filtration. It is well accepted 
that  the rate  of fall  of  glomerular  filtration rate  can be reduced from around 12 ml/min/year  to  5 
ml/min/year  if  arterial  blood  pressure  is  adequately  controlled.  With  aggressive  antihypertensive 
therapy, it is possible in at least some patients with persistent protienuria to reduce protein excretion 
into  the  microalbuminuric  range  for  several  years  and  to  maintain  the  glomerular  filtration  rate75 
Likewise, in type 1 patients with nephrotic range protienuria, good blood pressure control can reduce 
protein excretion to ,600 mg/24 hours for at least one year and decrease the 
rate of fall of the glomerular filtration rate76  Particularly in type 2 diabetes, but also in type 1 patients 
with more advanced renal disease, systemic blood pressure will be high despite prescription of the 
maximum tolerated dose of ACE inhibitor or ATIIRB.
                
             Addition of other agents to lower blood pressure further is imperative. In general, the number 
of agents needed increases as nephropathy advances and it is not uncommon for individuals with rising 
serum creatinine to require four or five different agents.
 The choice of additional agents is individual, there being no good add-on trials. It is logical to 
use a diuretic (thiazide or loop) early: patients are often salt overloaded and many of the trials of ACE 
inhibitors/ATIIRBs included a diuretic in their regimen. Thereafter, the choice rests on the individual’s 
circumstances.
  NOVEL THERAPIES
               A number of novel therapies have been demonstrated to reduce urine albumin excretion and 
prevent glomerulosclerosis in a variety of animal models of diabetes . To date, few of these have been 
tried  in  clinical  practice,  generally in  small,  short  term studies.  One therapy,  already available,  is 
aldosterone  blockade.  Activation  of  the  renin-angiotensin  system stimulates  aldosterone  secretion, 
which  may subsequently be involved in  renal  damage.  Aldosterone  levels  may ‘‘rebound’’  during 
treatment with inhibitors of the renin-angiotensin system. 
  There is also evidence that aldosterone, independently of the renin-angiotensin system, is an 
important pathogenic factor in progressive renal disease, promoting fibrosis and collagen formation77 In 
several experimental models, blockade of aldosterone reduces proteinuria. 
               In one small study of type 2 diabetic patients with early nephropathy already taking an ACE 
inhibitor, addition of spironolactone 25 mg/day resulted in a 40% decrease in urine albumin excretion 
and a significant reduction in left ventricular mass over 24 weeks78 In a study reported in abstract of 
hypertensive,  microalbuminuric  type  2  diabetic  patients,  the  selective  aldosterone  antagonist 
eplerenone reduced proteinuria at least as much as ACE inhibition79 Dual blockade resulted in a further 
reduction in proteinuria.
 Thus selective aldosterone blockade as monotherapy orin combination with inhibitors of the 
renin-angiotensin  system  is  a  potentially  useful  therapy  for  preventing  progression  of  diabetic 
nephropathy.
 
REVIEW OF LITERATURE
Schultz  et al.,80 in a hospital based longitudinal study of 514 children at United Kingdom, who 
developed type 1 diabetes before the age of 16 yrs , found that 12.8% developed microalbuminuria and 
was persistent in 22 (4.8%) of the subjects. HbA1c was worse in those who developed MA than in 
others (mean difference +/- SEM: 1.1% +/- 0.2, P < 0.001). In subjects who had been 5-11 years of age 
when their diabetes was diagnosed, the appearance of MA was delayed until puberty, whereas of those 
whose age was <5 years at diagnosis of diabetes, 5 of 11 (45%) developed MA before puberty. 
Holl  et  al.,  81 in  a  hospital  based  study comprising of  447  children  and  adolescents  with  type  1 diabetes  at 
Germany, found that, after a duration of diabetes of 11 years, 5% of patients displayed persistent microalbuminuria (10% 
after 13 years). The duration of diabetes until persistent microalbuminuria was identical for patients with prepubertal or 
pubertal onset of diabetes. In addition to duration, female sex (P < 0.03) and insufficient long-term metabolic control (P < 
0.03) contributed significantly and independently to urinary albumin excretion. 
Based on repeated measurements in individual patients, the positive predictive value of one sample was 76%, the 
negative 99.5%. When related to the duration of diabetes, 12 patients with persistent microalbuminuria had duration of 
diabetes <5 years (range 0-3.1).
           Stone et al.,82 in a hospital based longitudinal cohort of 972 children at Westmead Australia ,the 
incidence  of  persistent  microalbuminuria  was  4.6  (95% CI  3.3–6.1)  per  1,000  patient-years.  The 
median diabetes duration at the onset of persistent microalbuminuria was 9.3 years, and the earliest 
case was 1.6 years after diagnosis of diabetes. Predictors of persistent microalbuminuria from the first 
assessment using multiple logistic regression were high cholesterol [95% CI 1.2–4.0]) and borderline 
microalbuminuria (2.5 [1.2–5.2]). Predictors using Cox regression were HbA1c (hazard ratio 1.4 [95% 
CI 1.1–1.7]), age at diagnosis (1.2 [1.1–1.3]), obesity (3.6 [0.8–15.5]), and insulin dose (2.7 [1.0–7.5]).
Cosmescu A et al., 83 in a hospital based study at Romania, Out of 110 children and teenagers 
suffering  from  type1  diabetes  mellitus,  persistent  microalbuminuria  (the  incipient  diabetic 
nephnropathy) was detected in 9% and intermittent microalbuminuria in 11.8%. In all the cases, a poor 
glycaemic control was associated, the average HbA1c being higher than 10%.
 Moore TH et al84 in this centrally coordinated, cross sectional, multicentric study done in 22 
pediatric  diabetes outpatient clinics  in UK & Ireland, found that out of 1007 patients aged between 10 
to 20 years with IDDM , 9.7%  had  microalbuminuria. The mean duration of diabetes in this study 
group was 6 yrs.  Significantly more girls than boys (3:1) and significantly more pubertal  and post 
pubertal patients had abnormal albumin excretion. Microalbuminuria was not associated with raised 
blood pressure.  The mean HbA1c in  patients  with microalbuminuria was higher  than in those with 
normoalbuminuria.
Jones C A et al.,85  in  a hospital based longitudinal study over 8 years in 233 children with 
Insulin dependant diabetes mellitus attending a single pediatric diabetic clinic at Liverpool UK, found 
that,  14.5% had persistent microalbuminuria. Longer duration of diabetes and raised median HbA1c 
were found to be associated with persistent microalbuminuria. The onset of persistently raised ACR in 
13 of 34 children was before puberty and in 23 of 34 children it was within first 4 years of diagnosis. 
The cross sectional prevalence of  microalbuminuria was 12.9% at one year, 18.3% at 5 years and 33% 
at 10 yrs after diagnosis.
Francis J et al.,  86 reported from Birmingham, a case of 12 yr old asian girl with a 4 year 
history  of  poorly  controlled  insulin  dependant  diabetes  mellitus  who  developed  overt  diabetic 
nephropathy. Screening for microalbuminuria would have identified incipient diabetic nephropathy and 
highlighted  the  importance  of  good glycemic  control.  Although screening  for  microalbuminuria  is 
recommended after five years from diagnosis it may be appropriate to undertake this annually in those 
with poor glycemic control.
Bruno  G et  al.,87 found  that  out  of  298  subjects  with  IDDM with  3  to  9  years  duration, 
prevalence of microalbuminuria was 7% in subjects with duration 3-9 yrs, and 4% in subjects with 
duration of 3 to 5 years. In almost 50% of the cohort, HbA1c levels were over 9%, whereas only in 
10.9% HbA1c levels were lower than 6.6%. This shows a low prevalence of microalbuminuria in young 
subjects with short duration of IDDM, even if the glycemic control obtained was far from ideal.
               Bojesting M et al., 88 in a 10 year follow up of 109 patients found that, at initial investigation, 
81 patients had normal AER, 27 had microalbuminuria and 1 had microalbuminuria. Only 5 (19%) of 
the initially microalbuminuria patients developed, macroproteinuria during the 10 yrs follow up period, 
and in 15 (58%) patients, AER decreased to normal. Three (4%) of the  normoalbuminuric patients 
developed microalbuminuria  but  none  macroproteinuria.  The  initially  microalbuminuric  patients  in 
whom AER normalized had improved their glycemic control over 10 yrs. Hence in the majority of 
patients  with  microalbuminuria  in  whom  it  is  possible  to  obtain  good  glycemic  control, 
microalbuminuria will disappear and the risk of nephropathy will be markedly reduced.
Powrei JK et al., 89   in a 10 yrs prospective study of a cohort of IDDM patients attending single 
out patience clinic at London found that, 8 of the 97 patients had developed microalbuminuria by the 
10 yr follow up. Multiple linear regression analysis showed that urinary ACR at 10 yrs was influenced 
by initial albumin creatinine ratio, initial glycated hemoglobin concentration, & duration of diabetes. 
The development of microalbuminuria is determined primarily by poor long term glycemic control. 
There is a weaker relation with longer duration of disease and younger age at onset of diabetes, but 
blood pressure does not seem to be implicated.
.
Rudberg S et al.,  90 in a 15 yr follow up study from onset in 156 type I diabetic children  at 
Sweden found that the cumulative incidence of microalbuminuria by duration was 24.2% at 15 yrs of 
diabetes. Eleven patents developed microalbuminuria after more than 5 years. Six patients had an onset 
before 5 years of diabetes. The relative importance of early versus later hyperglycemia, yearly blood 
pressure, age, age at onset and duration of diabetes for increased albumin excretion rate after more than 
5 years, was shown in a multiple regression analysis where the first 5 year mean HbA1c was the only 
independent predictor.
Mathiesen ER et al 91 Studied a total of 102 diabetic children attending 2 diabetic clinics in the 
age group of 7 to 18 yrs with more than 2 years of diabetic duration and found that, 20% had persistent 
microalbuminuria. Microalbuminuria was only demonstrated in patients aged more than or equal to 15 
years,  prevalence  of  37%.  Arterial  blood  pressure  was  elevated  in  the  microalbuminuria  group 
compared  to  age  matched  normoalbuminuric  diabetic  group.  HbA1c  was  slightly  higher  in  the 
microalbuminuric patients, p<0.10.
Barkai et al., 92 in a prospective study done in normoalbuminuric prepubertal (n=20), pubertal 
(n=28), & post pubertal (n=26) IDDM group matched for diabetic duration & long term metabolic 
control & were followed up for 3 years, found that AER increased significantly over a period of 3 years 
in  the pubertal  (p=0.001)  & post  pubertal  (p=0.003)  subjects  but  not  in  pre pubertal  subjects.  Six 
pubertal, 2 postpubertal and none of the pre pubertal subjects developed microalbuminuria. Multiple 
logistic regression analysis showed that puberty represents an independent risk for the development of 
microalbuminuria in diabetes.
Bravo  RLE  et  al.,  93 studied  160  Insulin  Dependant  Diabetic  Children  attending  a  single 
outpatient  clinic  and  found  that  8%  had  microalbuminuria  and  3%  had  clinical  protienuria.  The 
abnormal  excretion was more prevalent  in  females with the poorest  metabolic  control,  the longest 
duration of diabetes, and the highest age (13-18 years).
 Pedro Gonzalez  et al., 94  studied 30 children with type I diabetes in the age group of 2 to 16 
yrs and found that, microalbuminuria was found in 12 (40%) of patients, with a greater frequency in 
those in pubertal age and with greater time of evolution. Whereas sex and metabolic control did not 
influence.
STUDY JUSTIFICATION
Diabetic nephropathy is the single most common cause of end stage renal disease95 .It accounts 
for 30 to 35 % of diagnoses leading to ESRD 96. Approximately 35 to 45 % of Type 1 diabetics develop 
nephropathy  55.The  devastating  renal  consequences  of  diabetes  mellitus  highlight  its  potential  for 
significant morbidity and emphasize that better understanding of its pathogenesis is needed to heighten 
clinical suspicion of early kidney involvement.
           
Several  longitudinal observations have provided insight into the natural history  of diabetic 
nephropathy, facilitating identification of renal involvement in its earliest stages .A most significant 
observation has been the recognition that microalbuminuria identifies the diabetic at risk for developing 
renal insufficiency. Its presence confers incipient nephropathy and heralds likely progression to end 
stage renal failure.
           
Viberti and co – workers first described microalbuminuria as a risk factor  for renal disease , in 
that , patients with microalbuminuria  were 20 times more likely to develop clinical protienuria than 
patient with normoalbuminuria 97 , an observation that was upheld by subsequent investigations 5,98, 99. 
About 80% of Type 1 diabetics with microalbuminuria go on to develop clinical nephropathy. Recent 
works  show  that  microalbuminuria  is  not  only  a  marker  of  impending  diabetic  nephropathy,  but 
indicates presence of abnormal glomerular metabolic function. 
           
    In previous studies microalbuminuria has been detected in 7- 20 % of young adults and 
children  with  IDDM  100,101,102,103.  American  diabetes  Association104 and  International  Society  for 
Pediatric and Adolescent Diabetology (ISPAD) 105, recommends screening for all patients with duration 
of diabetes > 5 years or with chronological age > 11 years. But many studies 85, 86 have also reported 
incidence of microalbuminuria and overt diabetic nephropathy in children < 5 yrs of diabetic duration.
                Hence it is imperative that all diabetic children need to be screened for microalbuminuria to 
detect diabetic nephropathy in its earliest stage. 
                AIM
1. To  determine  the  cross  sectional  prevalence  of  microalbuminuria  in  children  attending  our 
diabetic clinic.
2. To assess the factors likely to increase the risk of microalbuminuria.
SUBJECTS AND METHODS
Study Design                 :             Descriptive Study.
Study Place                   :             Institute Of Child Health and Hospital 
                                                     For Children - Chennai.
Study Period                 :             March 2005 to July 2006.
Sample Size                   :             125
Study Population
Inclusion Criteria         :             All Children with Diabetes Mellitus 
                                                      Attending the Diabetic Clinic at ICH & 
                                                      HC.
                 
Exclusion Criteria        :             Children with Known Renal Disease And 
                                                      Those on Reno Toxic Drugs Are Excluded.
Manoeuvre   
           
125 children with diabetes mellitus attending the diabetic clinic ICH & HC were recruited 
consecutively, irrespective of duration of diabetes. Those with known renal isease and those on Reno 
toxic chemotherapy were excluded from the study. After obtaining informed consent from the parents, 
a preformed Proforma was filled.
            Height was measured to nearest 0.1 cm using standardized Harpeden Stadiometer. Weight was 
measured to nearest  500 gms using standardized bathroom scale.  Blood pressure was measured in 
sitting posture in right upper limb using a standard sphygmomanometer after five minutes of rest.
           Three morning urine samples 5ml from each patient was collected over a period of 1 year at 3 to 
6 months interval. The presence of urinary tract infection or microhematuria was excluded by dipstick 
detection.  Urine  sample  were  not  included  in  the  study if  either  microhematuria  or  urinary  tract 
infection were present. Girls were asked not to collect urine during menstruation and wait for three 
days  after  the last  day of  bleeding.  The concentration of  albumin in  the urine was determined by 
radioimmunoassay and the concentration of creatinine by jaffe’s method. The ACR was calculated for 
each patient for each collection.
          Corresponding blood samples were taken to assess long term metabolic control by estimating 
HbA1c.It  was estimated by high performance liquid chromatography.           Urea,  creatinine and 
ultrasound abdomen was done to all patients at the time of recruitment, to rule out other existing renal 
diseases.  Fundus  examination  was  done  to  all  patients  once  during  the  study  period  by  the 
Ophthalmologist.
 
Statistical Analysis:
All results were tabulated and percentage was arrived by using windows MS Excel application 
and  analysis  was  performed  by  using  SPSS  version  11.0-Software.  Descriptive  statistics  like 
frequencies  and percentages  were  obtained. Chi-square  test  was  done  to  compare  between various 
groups.  P value less than 0.05%was considered significant.  
DEMOGRAPHY
Table .1
AGE DISTRIBUTION OF STUDY POPULATION
CHART 1
47%
39%
14%
< 5 years
5 - 11 years
>11 years
RESULT:
                47.2% of children were between 5 to 11 years, and 39.2% above 11 years and 13.6% were  
below 5 years.76 children were prepubertal.
Table .2
                                     GENDER DISTRIBUTION 
Sex N %
Male 54 43.2
Female 71 56.8
Total 125 100
CHART.2
54
43%
71
57%
Male
Female
RESULTS
                 Slight female preponderance was noted in the study .Male female ratio
Was 1:1.3.
                                                                
                                                              Table 3
DISTRIBUTION OF CHILDREN AS PER AGE AT ONSET OF DIABETES
Age n %
< 5 years 39 31.2
5 - 11 years 77 61.6
>11 years 9 7.2
Total 125 100
CHART.3
39
31%
77
62%
9
7%
< 5 years
5 - 11 years
>11 years
RESULTS:
                     61.6% were diagnosed to have diabetes between 5 to 11 years of age. 39(31.2%) were 
below five years at the time of diagnosis, followed by 9(7.2%) above 11years at the time of diagnosis.
Table 4
DISTRIBUTION OF DIABETIC AGE
Duration n %
< 1 year 22 17.6
1 to 5 years 89 71.2
>5 years 14 11.2
Total 125 100
CHART.4
89
71%
14
11%
22
18%
< 1 year
1 to 5 years
>5 years
RESULTS:
                  71.2% children of the study population had diabetic duration of 1 to 5 years followed by 
17.6% children with less than one year of duration.  Children with more than five year of diabetic 
duration comprised 11.2 %.
Table 5
MEAN AND STANDARD DEVIATION OF STUDY PARAMETERS 
Particulars Mean S.D.
Age 10.1 3.7
Age at onset of diabetes 6.9 3.3
Diabetic age 3.2 2.0
HbA1c 12.5 3.0
CHART.5
10.1
6.9
3.2
12.5
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
Age Age at onset of diabetes Diabetic age HbA1c
M
EA
N
RESULTS:
The Mean Age of Our Study Population Is 10.1 (SD 3.7).
The Mean Age at Onset Of Diabetes Is 6.9 (SD 3.3).
The Mean Diabetic Duration Is 3.2(SD 2.0).
            The Mean HbA1C Is 12.5(SD 3.0)
Table: 6
MEAN AND SD OF SEX DISTRIBUTION vs.  AGE, AGE AT ONSET OF 
DIABETES AND DIABETIC AGE
Male Female
Mean S.D. Mean S.D.
Age 9.7 3.4 10.3 3.9
Age at onset of diabetes 6.7 3.0 7.0 3.5
Diabetic age 3.0 2.0 3.3 1.9
9.7 10.3
6.7 7.0
3.0 3.3
0.0
2.0
4.0
6.0
8.0
10.0
12.0
M
EA
N
AGE AGE AT
ONSET OF
DIABETES
DIABETIC
AGE
CHART.6
Male
Female
RESULTS:
                  Mean of age, age at onset of diabetes and diabetic duration of the female children were 
found higher when compared to the male children.
                                                     
Table 7
 MICROALBUMINURIA IN THE STUDY POPULATION.
n %
Normoalbuminuria 95 76
Persistent Microalbuminuria 7             5.6
Intermittent Microalbuminuria 23 18.4
Total 125 100
CHART.7
95
76%
7
6%
23
18%
Normoalbumunurea
Persistent Microalbuminuria
Intermittent Microalbuminuria
RESULTS:
                 18.4% intermittently developed UAC in the microalbuminuric range (>30 mcg/mg) in 
only one of the 3 samples. 7(5.6%) children in the total cohort developed persistent microalbuminuria 
i.e., 2 out of 3 consecutive samples.
Table 8
GENDER   DISTRIBUTION vs. MICROALBUMINURIA
Male Female
N % n % p value
Persistent Microalbuminuria 4.0 7.4 3.0 4.2 0.5
Intermittent Microalbuminuria 7.0 13.0 16.0 22.5 0.2
Microalbuminuria(Total) 11.0 20.4 19.0 26.7 0.5
Persistent Microalbuminuria Intermittent Microalbuminuria
Male
female
3.0
16.0
4.0
7.0
CHART.8
RESULTS:
                  There is no sex prepondence in children developing persistent microalbuminuria, with 
3(4.2%) female and 4(7.4%) male children developing persistent microalbuminuria.
Table 9
PUBERTY vs.   MICROALBUMINURIA
N %
Normoalbuminuria
Persistent 
microalbuminuria
P 
value
N % n %
Age
< 5 years 17.0 13.6 16.0 94.1 1.0 5.9
5 – 11 
years 59.0 47.2 58.0 98.3 1.0 1.7
> 11 
years 49.0 39.2 44.0 89.8 5.0 10.2 0.2
CHART.9
16.0
1.0
58.0
1.0
44.0
5.0
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
Normal albuminuria Persistant Microalbuminuria
PO
PU
LA
TI
O
N
Age < 5 years
Age 5 - 11 years
Age > 11 years
RESULTS:
                   5 out of 7 developed microalbuminuria after  onset of puberty.  Only 5 children 
(10.2%)above the age of 11years developed persistent microalbuminuria and this was  not statistically 
significant. (p= 0.2)
Table 10
 PUBERTAL ONSET OF DIABETES vs.   MICROALBUMINURIA
N %
Microalbuminuria
Normal Persistent
   N % n %
P 
value
Age at onset of 
diabetes
< 5 years 39.0 31.2 38.0 97.4 1.0 2.6
5 – 11 years 77.0 61.6 72.0 93.5 5.0 6.5
>11 years 9.0 7.2 8.0 88.9 1.0 11.1 0.5
38.0
1.0
72.0
5.0
8.0
1.0
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
PO
P
U
LA
TI
O
N
< 5 years 5 - 11 years >11 years
CHART.10
Persistant Microalbuminuria
Normal albuminuria
RESULTS:
                  In the above 11 years group, out of 9 children only 1 child  11.1% developed 
microalbuminuria. Most of the children developing persistent microalbuminuria were 5 to 11 years of 
age at onset of diabetes. 
Table 11
DIABETIC DURATION   vs.   MICROALBUMINURIA
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Persistent Microalbuminuria
Normal albuminuria
RESULTS:
                   In our study population out of 14 children with more than five years of duration only 1 
child i.e., 7.1% developed microalbuminuria which is not statistically significant. Whereas 5(5.6%) out 
of 89 children with duration of 1 to 5 years developed microalbuminuria and 1(4.5%) child below one 
year age developed microalbuminuria.
Table 12
HbA1c
HbA1c
Mean SD
Normoalbuminuria 12.3 3.0
Persistent Microalbuminuria 13.3 2.4
Total study population 12.5 3.0
RESULTS:
                        The HbA1c of our study population was 12.5(SD 3.0). the mean HbA1C of children with 
persistent microalbuminuria was 13.3(SD 2.4) as against 12.3(SD 3.0) among normoalbuminuric 
group.   There was no Statistical significance in the mean HbA1c of the two groups.  
Table 13
Univariate Logistic Regression Of persistent microalbuminuria
Variables O.R. 95% C.I. p-value
Age at onset of diabetes 0.5
< 5 years  0.5       0.05 , 4.2
5 - 11 years 1.0 Reference
>11 years 2.5     0.2 , 26
Duration of diabetes    0.9
< 1 year 1.0 Reference
1 to 5 years 1.5 0.2 , 13.3
>5 years 1.7 0.1 , 30.5
HbA1c 1.5 0.2 , 13.2    0.7
                                          
  RESULTS:
                            Univariate logistic regression analysis of variables – age at onset of diabetes, duration 
of diabetes, and HbA1C did not reveal any significance.    
          
                     The sensitivity of one elevated urinary albumin excretion rate to detect persistent 
microalbuminuria was 64% and specificity was 90%. The positive predictive value of one urine 
albumin measurement was 39% and the negative predictive value was96% (95% CI 91%, 99%).
                   Using the accepted definition of severe hypertension in childhood systolic and /or diastolic 
blood pressure equal to or greater than the 95th percentile for age and sex none of the children in our 
study population were hypertensive.
                   On Fundus examination none of our children showed evidence of diabetic retinopathy. 
                                 DISCUSSION
               125 children recruited for study from our diabetic clinic were, in the age group of 2 to 16 
years, the mean age was 10.2 +/- 3.0. The youngest child was 2.4years of age. Literature review reveals 
studies on microalbuminuria in IDDM children with a mean age of 13 +/- 4 years Bravo et al93, 10-20 
yrs in MIDAC study group84. How ever there is a similar study with age group of 2 to 16 years by 
Pedro et al 94.Most of the literature on microalbuminuria reveal the mean age of the population to be in 
the higher range, as adolescents are included in the pediatric population. 86.4% of our study group 
comprised of children above five years and only 13% of them were below 5 years i.e.,  pre-school 
children. 
                 
            Gender distribution of our population revealed that female children predominated in this study. 
They consisted about 56.8%, whereas the total male children were 43.2%. The male female ratio was 
1:1.3.On the contrary it was 1:3 in MIDAC study group84.
             Age at diagnosis of diabetes mellitus was taken as the age of onset of diabetes and this revealed 
60% of our children were in the age group between 5 to 11 years and about  1/3rd were below 5 years. 
Only 7.2% were above 11 years of age at onset. This shows that most of our children had pre pubertal 
onset of diabetes mellitus (93%).           
              The diabetic age of our population revealed that majority of our children (89%) had a diabetic 
age of less than 5 years. Only 11% had diabetic duration over 5 years. The least duration being one 
month.
            Mean age, age of onset of diabetes and diabetic age of the female children were found to be 
higher when compared to male children, but this was not statistically significant.
Microalbuminuria:
           Based on the albumin creatinine ratio of early morning urine samples, 18.4 % ( 23) of our study 
population intermittently developed microalbuminuria (ACR more than 30mcg/mg) in only one of the 
three  consecutive  samples.  5.6  %(  7)  of  children  in  the  total  cohort  developed  persistent 
microalbuminuria i.e.,  ACR more than 30mcg/mg in two of the three consecutive samples.  Of the 
seven children with persistent microalbuminuria 5 were in the age group of more than 11yrs and one 
child each in the age group of 5 to 11 years and below five year. The youngest being 4 years of age 
with diabetic age of 11 months.
              The prevalence of microalbuminuria of 5.6% in our study is much lower than the studies done 
previously elsewhere in different population. 9.8% in MIDAC study group84, 8% in the study by Bravo 
et al 93, 9% in the study by Cosmescu et al 83 and 12.9% by Jones et al 85. The world wide prevalence is 
between 7 to 20 percent .The reasons attributable could be that the age group selected for the study in 
the first groups was much different from our study group. Most of our children were in the prepubertal 
age.  Several  Retrospective  and cross  sectional  studies  found a  relationship  between occurrence  of 
microalbuminuria and the pubertal period. And suggested that puberty may play a critical role in the 
development of DN 100, 106,107,108.This findings suggest that the endocrine changes of puberty lead to an 
accelerated process of early kidney damage in diabetes. Studies of similar nature in pubertal children 
with type 1 DM would probably reveal higher  prevalence than the present study which comprises 
predominantly of prepubertal children 61%.  
              Gender distribution, age at onset of diabetes and diabetic age did not reveal any statistical  
significance in children with persistent microalbuminuria which is in concordance with the study by 
Pedro et al94.
              Various studies done by bravo et al, Holl et al 81, Cosmescu et al 83, Jones et al 85, MIDAC 
study group84, ORPS80, reveal that more girls than boys, more pubertal children and those with longer 
duration of diabetes( > 5 years) have increased risk of developing microalbuminuria.
              The mean HbA1c of our study population was 12.5 which indicate a poor glycemic control in 
our population. This could be attributable to lack of frequent home based blood glucose monitoring due 
to economic constraints in our study population. This again emphasizes that home based frequent BG 
monitoring is essential in diabetic children for long term glycemic control which is a must for avoiding 
long term complications in diabetes.
                   In this context, in our study comparing microalbuminuric group and normoalbuminuric 
group, there was no statistically significant difference in mean HbA1c.
              
                  On the contrary studies by Bravo et al 93, Holl et al 81, Cosmescu et al 83, MIDAC study 
group 84, ORPS 80, show that poor metabolic control was significantly associated with development of 
microalbuminuria. The mean HbA1C of the microalbuminuric children being 10% in Cosmescu et al 83. 
In the study by Bruno et al87 50% of the cohort had HbA1c levels over 9% and only 10 % had the levels 
below 6.6%. In ORPS80, the mean HbA1c of the total cohort was 9.9% +/- 1.7. The mean HbA1c was 
significantly greater in children who developed microalbuminuria (mean difference+/- SEM : 1.1% +/- 
0.2).
             Among our study population 18 children were positive for microalbuminuria in the first 
sample.7 children among them had persistent  microalbuminuria.  4  children  tested  negative in  first 
sample and positive in second sample.
              The  sensitivity  of  one  elevated  urinary albumin  excretion  rate  to  detect  persistent 
microalbuminuria  was  64% and  specificity  was  90%.  The  positive  predictive  value  of  one  urine 
albumin measurement was 39% and the negative predictive value was96% (95% CI
91%,  99%).This  was  similar  to  the  observation  by Holl  et  al  81,  with  the  sensitivity  of  76% and 
specificity of 95.8%.  Their PPV was 40.6% and NPV was 99.5%.
              It has to be kept in mind that the predictive values of a positive screening result depend on the prevalence of the 
disease in the respective population. Persistent microalbuminuria is quiet rare in pediatric subjects upto early adulthood. In 
our study a single value in the microalbuminuric range conveys only a 39% chance to indicate persistent microalbuminuria 
in pediatric patients.
 
            Medically, this demands that other potential causes of microalbuminuria have to be excluded (urinary tract infection 
and nondiabetic kidney diseases such as IgA nephritis, febrile proteinuria, etc.) and elevated albumin excretion has to be 
confirmed by at  least  one  more  measurement  before  a  diagnosis  of  incipient  diabetic  nephropathy can  be  made and 
therapeutic  consequences  are  justified.  In  addition,  this  high  rate  of  false-positive  results  may  lead  to  unnecessary 
psychological  disturbance  of  patients  and  their  families.  However,  the  intra-individual  variability  of  urinary  albumin 
excretion should not be used to support a nihilistic approach to routine screening in pediatric patients.
         
                              CONCLUSION
• The prevalence of microalbuminuria in the pediatric population attending our diabetic clinic is 5.6%.
• Pubertal age and increasing duration of diabetes, appears to be associated with increased risk of microalbuminuria 
but is not statistically significant.
• Gender and age at onset of diabetes were not associated with increased risk of persistent microalbuminuria.
• In  agreement  with recommendations  by the  American  Diabetes  Association and  the  International  Society for 
Pediatric  and  Adolescent  Diabetology  (ISPAD),  the  German  Working  Group  on  Pediatric  Diabetology 
recommends screening for all patients with a duration of diabetes >5 years or with a chronological age >11 years. 
Following  these  guidelines,  in  our  patient  population  2  children  with  persistent  proteinuria  <11  years  and  6 
children with duration less than 5 years would have been missed. 
      Recommendations:
• Children with lesser diabetic age (<5years) also need to be investigated for microalbuminuria.
• Similar  studies  in  larger  groups  are  needed  to  identify  the  risk  factors  in  our  population  so  that  necessary 
recommendations can be made to diagnose diabetic nephropathy much earlier in the risk group.   
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ANNEXURE
PROFORMA
Diabetic Clinic No. :
Name :
Age :
Age at onset                                       :
Age at Diagnosis :
Sex :
Diabetes Duration :
H/O Renal Disease :
Family History of DM :
On Examination :
 Height in cms 
 Weight in Kg
 Blood Pressure
Fundus Examination
     Investigations :
• Urine   - Albumin
                   Ketone Bodies
                   Puscells / Deposits
   
•  Blood   - Urea
       Serum  - Creatinine
• Ultra sound abdomen
Test Date /Sample I Sample II Sample III
Urine
Microalbuminuri
a
HbA1c
 
                                          ABBREVIATIONS
• ACR                               Albumin Creatinine Ratio
• AER                               Albumin Excretion Rate
• AGE                               Advanced Glycation End Products
• ACE                               Angiotensin Converting Enzyme
• ATIIRB                          Angiotensin  II Receptor Antagonist 
• CRP                                C Reactive Protien
• DN                                  Diabetic Nephropathy
• ESRD                             End Stage Renal Disease
• GBM                              Glomerular Basement membrane
• GFR                               Glomerular Filtration Rate
• IDDM                             Insulin Dependent Diabetes Mellitus
• ISPAD                            International Society for Pediatric and Adolescent 
                                             Diabetology.
• MIDAC                          Microalbuminuria In Diabetic and Adolescent children
• NPV                               Negative Predictive Value
• ORPS                             Oxford Regional Prospective Study
• PRA                                Plasma Renin Activity
• PPV                                Positive Predictive Value
• RAS                                Renin Angiotensin System
• RAGE                             Receptor for AGE
• ROS                                Reactive Oxygen Species
• SD                                  Standard Deviation
• TBM                              Tubular  Basement Membrane
• UAC                              Urinary Albumin Concentration
